<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-14T04:12:00Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:2072/459274" metadataPrefix="oai_dc">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:2072/459274</identifier><datestamp>2026-03-13T08:02:16Z</datestamp><setSpec>com_2072_98</setSpec><setSpec>col_2072_378192</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
   <dc:title>Cell Death Triggered by the Autophagy Inhibitory Drug 3-Methyladenine in Growing Conditions Proceeds With DNA Damage</dc:title>
   <dc:creator>Chicote, Javier</dc:creator>
   <dc:creator>Yuste, Victor José</dc:creator>
   <dc:creator>Boix, Jacint</dc:creator>
   <dc:creator>Ribas, Judit</dc:creator>
   <dc:subject>3-methyladenine</dc:subject>
   <dc:subject>Autophagy inhibitor</dc:subject>
   <dc:subject>Basal autophagy</dc:subject>
   <dc:subject>Ɣ-H2A.X</dc:subject>
   <dc:subject>Apoptosis</dc:subject>
   <dc:description>Macroautophagy (hereafter autophagy) is a multistep intracellular catabolic process with pleiotropic implications in cell fate. Attending to its activation, autophagy can be classified into inducible or constitutive. Constitutive, or basal autophagy, unfolds under nutrient-replete conditions to maintain the cellular homeostasis. Autophagy inhibitory drugs are powerful tools to interrogate the role of autophagy and its consequences on cell fate. However, 3-methyladenine and various of these compounds present an intrinsic capacity to trigger cell death, for instance the broadly-employed 3-methyladenine. To elucidate whether the inhibition of basal autophagy is causative of cell demise, we have employed several representative compounds acting at different phases of the autophagic process: initiation (SBI0206965 and MHY1485), nucleation (3-methyladenine, SAR405, Spautin-1 and Cpd18), and completion (Bafilomycin A and Chloroquine). These compounds inhibited the basal autophagy of MEF cultures in growing conditions. Among them, 3-methyladenine, SBI-0206965, Chloroquine, and Bafilomycin A triggered BAX- and/or BAK-dependent cytotoxicity and caspase activation. 3-methyladenine was the only compound to induce a consistent and abrupt decrease in cell viability across a series of ontologically unrelated human cell lines. 3-methyladenine-induced cytotoxicity was not driven by the inhibition of the AKT/mTOR axis. Autophagy-deficient Fip200-/- MEFs displayed an increased sensitivity to activate caspases and to undergo cell death in response to 3-methyladenine. The cytotoxicity induced by 3-methyladenine correlated with a massive DNA damage, as shown by γ -H2A.X. This genotoxicity was observed at 10 mM 3-methyladenine, the usual concentration to inhibit autophagy and was maximized in Fip200-/- MEFs. In sum, our results suggest that, in growing conditions, autophagy acts as a protective mechanism to diminish the intrinsic cytotoxicity of 3-methyladenine. However, when the cellular stress exerted by 3-methyladenine surpasses the protective effect of basal autophagy, caspase activation and DNA damage compromise the cell viability.</dc:description>
   <dc:date>2020</dc:date>
   <dc:type>Article</dc:type>
   <dc:identifier>https://ddd.uab.cat/record/253081</dc:identifier>
   <dc:identifier>urn:10.3389/fphar.2020.580343</dc:identifier>
   <dc:identifier>urn:oai:ddd.uab.cat:253081</dc:identifier>
   <dc:identifier>urn:articleid:16639812v11</dc:identifier>
   <dc:identifier>urn:pmcid:PMC7593545</dc:identifier>
   <dc:identifier>urn:pmc-uid:7593545</dc:identifier>
   <dc:identifier>urn:pmid:33178023</dc:identifier>
   <dc:identifier>urn:oai:pubmedcentral.nih.gov:7593545</dc:identifier>
   <dc:identifier>urn:oai:egreta.uab.cat:publications/7e253b9a-65be-4001-98c9-6c5fe43a24f6</dc:identifier>
   <dc:identifier>urn:scopus_id:85094571451</dc:identifier>
   <dc:language>eng</dc:language>
   <dc:relation>Agencia Estatal de Investigación SAF2016-78657-R</dc:relation>
   <dc:relation>Frontiers in Pharmacology ; Vol. 11 (october 2020)</dc:relation>
   <dc:rights>open access</dc:rights>
   <dc:rights>Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.</dc:rights>
   <dc:rights>https://creativecommons.org/licenses/by/4.0/</dc:rights>
   <dc:format>application/pdf</dc:format>
   <dc:publisher/>
</oai_dc:dc></metadata></record></GetRecord></OAI-PMH>